Walleye Capital LLC Grows Stake in Sotera Health (NASDAQ:SHC)

Walleye Capital LLC increased its holdings in shares of Sotera Health (NASDAQ:SHC - Free Report) by 818.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 775,000 shares of the company's stock after purchasing an additional 690,597 shares during the quarter. Walleye Capital LLC owned approximately 0.27% of Sotera Health worth $10,602,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in Sotera Health by 19.4% during the third quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company's stock worth $46,026,000 after buying an additional 447,186 shares during the period. Barclays PLC raised its position in Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company's stock valued at $7,909,000 after purchasing an additional 298,085 shares during the last quarter. KBC Group NV boosted its stake in Sotera Health by 4,094.6% during the 4th quarter. KBC Group NV now owns 186,365 shares of the company's stock worth $2,549,000 after purchasing an additional 181,922 shares during the period. SG Americas Securities LLC grew its position in Sotera Health by 271.6% during the 4th quarter. SG Americas Securities LLC now owns 36,364 shares of the company's stock worth $497,000 after purchasing an additional 26,577 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its stake in Sotera Health by 17.3% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,839 shares of the company's stock valued at $217,000 after purchasing an additional 2,340 shares during the period. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Stock Performance

NASDAQ SHC traded down $0.01 on Friday, hitting $10.48. 858,965 shares of the company's stock were exchanged, compared to its average volume of 1,202,288. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of 41.92 and a beta of 1.88. The firm's 50-day moving average price is $11.82 and its two-hundred day moving average price is $13.30. Sotera Health has a fifty-two week low of $9.53 and a fifty-two week high of $17.08. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61.

Analysts Set New Price Targets

Separately, Barclays lowered their price target on Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Sotera Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.20.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.